The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
Clozapine versus typical neuroleptic medication for schizophrenia
Open accessAbstract
BACKGROUND: Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to have superior efficacy and to cause fewer motor adverse effects than typical drugs for people with treatment-resistant illnesses. Clozapine carries a significant risk of serious blood disorders, which necessitates mandatory weekly blood monitoring at least during the first months of treatment. OBJECTIVES: To evaluate the effects of clozapine compared with typical antipsychotic drugs in people with schizophrenia. SEARCH STRATEGY: For the current update of this review (March 2006) we searched the Cochrane Schizophrenia Group Trials Register. SELECTION CRITERIA: All relevant randomised clinical trials (RCTs). DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed-effect model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a fixed-effect model. MAIN RESULTS: We have included 42 trials (3950 participants) in this review. Twenty-eight of the included studies are less than 13 weeks in duration, and, overall, trials were at significant risk of bias. We found no significant difference in the effects of clozapine and typical neuroleptic drugs for broad outcomes such as mortality, ability to work or suitability for discharge at the end of the study. Clinical improvements were seen more frequently in those taking clozapine (n=1119, 14 RCTs, RR 0.72 CI 0.7 to 0.8, NNT 6 CI 5 to 8). Also, participants given clozapine had fewer relapses than those on typical antipsychotic drugs (n=1303, RR 0.62 CI 0.5 to 0.8, NNT 21 CI 15 to 49). BPRS scores showed a greater reduction of symptoms in clozapine-treated patients, (n=1145, 16 RCTs, WMD -4.22 CI -5.4 to -3.1), although the data were heterogeneous (Chi(2) 0.0001, I(2) 66%). Short-term data from the SANS negative symptom scores favoured clozapine (n=196, 5 RCTs, WMD -5.92 CI -7.8 to -4.1). We found clozapine to be more acceptable in long-term treatment than conventional antipsychotic drugs (n=982, 16 RCTs, RR 0.60 CI 0.5 to 0.7, NNT 15 CI 12 to 20). Blood problems occurred more frequently in participants receiving clozapine (3.2%) compared with those given typical antipsychotics (0%) (n=1031, 13 RCTs, RR 7.09 CI 2.0 to 25.6). Clozapine participants experienced more drowsiness, hypersalivation, or temperature increase, than those given conventional neuroleptics. However, clozapine patients experienced fewer motor adverse effects (n=1433, 18 RCTs, RR 0.58 CI 0.5 to 0.7, NNT 5 CI 4 to 6).The clinical effects of clozapine were more pronounced in participants resistant to typical neuroleptics in terms of clinical improvement (n=370, 4 RCTs, RR 0.71 CI 0.6 to 0.8, NNT 4 CI 3 to 6) and symptom reduction. Thirty-four per cent of treatment-resistant participants had a clinical improvement with clozapine treatment. AUTHORS' CONCLUSIONS: Clozapine may be more effective in reducing symptoms of schizophrenia, producing clinically meaningful improvements and postponing relapse, than typical antipsychotic drugs - but data are weak and prone to bias. Participants were more satisfied with clozapine treatment than with typical neuroleptic treatment. The clinical effect of clozapine, however, is, at least in the short term, not reflected in measures of global functioning such as ability to leave the hospital and maintain an occupation. The short-term benefits of clozapine have to be weighed against the risk of adverse effects. Within the context of trials, the potentially dangerous white blood cell decline seems to be more frequent in children and adolescents and in the elderly than in young adults or people of middle-age.The existing trials have largely neglected to assess the views of participants and their families on clozapine. More community-based long-term randomised trials are needed to evaluate the efficacy of clozapine on global and social functioning as trials in special groups such as people with learning disabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Short-term retention of individual verbal items.
Peterson, L., & Peterson, M. J. (1959) · Journal of Experimental Psychology · doi:10.1037/h0049234 · Cited by 2,939
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Evaluating storage, retention, and retrieval in disordered memory and learning
BUSCHKE, H., & FULD, P. A. (1974) · Neurology · doi:10.1212/wnl.24.11.1019 · Cited by 1,597
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Ukoumunne, Gulliford, Chinn, Sterne, & Burney (1999) · Health Technology Assessment · doi:10.3310/hta3050 · Cited by 1,210
Contributions to Neuropsychological Assessment
Sarazin, F. (1996) · Europe PMC (PubMed Central) · Cited by 1,151
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
Gulliford, M. C., Ukoumunne, O. C., & Chinn, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009904 · Cited by 852
Bland, J. M., & Kerry, S. M. (1997) · BMJ · doi:10.1136/bmj.315.7108.600 · Cited by 754
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Clozapine: A Novel Antipsychotic Agent
Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 687
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Boissel, J., Cucherat, M., Li, W., Châtellier, G., Gueyffier, F., Buyse, M. E., Boutitie, F., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 533
Novel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510
Treatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 491
Contributions to Neuropsychological Assessment: A Clinical Manual, 2nd Ed.
Adams, N. (1995) · Neurology · doi:10.1212/wnl.45.8.1637-a · Cited by 490
Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Honigfeld, G., & Klett, C. J. (1965) · Journal of Clinical Psychology · doi:10.1002/1097-4679(196501)21:1<65::aid-jclp2270210122>3.0.co;2-i · Cited by 435
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Self-citationPickar, D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050009001 · Cited by 354
Lieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.43 · Cited by 289
Buchanan, R. W., Holstein, C., & Breier, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Povlsen, U. J., Norrng, U., Fog, R., & Gerlach, J. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb01268.x · Cited by 278
The history of clozapine and its emergence in the US market: a review and analysis
Crilly, J. (2007) · History of Psychiatry · doi:10.1177/0957154x07070335 · Cited by 272
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Modafinil Improves Cognition and Attentional Set Shifting in Patients with Chronic Schizophrenia
Turner, D. C., Clark, L., Pomarol-Clotet, E., McKenna, P., Robbins, T. W., & Sahakian, B. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300457 · Cited by 258
Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
Chakos, M., Lieberman, J., Alvir, J., Bilder, R., & Ashtari, M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90441-7 · Cited by 250
Positron emission tomography: establishing priorities for health technology assessment.
Robert, G., & Milne, R. (1999) · PubMed · Cited by 248
Lindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
A new five factor model of schizophrenia
Lindenmayer, J.-P., Bernstein-Hyman, R., & Grochowski, S. (1994) · Psychiatric Quarterly · doi:10.1007/bf02354306 · Cited by 243
Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1164 · Cited by 238
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Self-citationEffects of clozapine on auditory event-related potentials in schizophrenia
Umbricht, D., Javitt, D., Novak, G., Bates, J., Pollack, S., Lieberman, J., & Kane, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00524-6 · Cited by 236
Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10170 · Cited by 233
Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.130 · Cited by 233
Clozapine in treatment-resistant schizophrenics.
Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. Y. (1988) · PubMed · Cited by 217
Clozapine-induced agranulocytosis: A genetic and epidemiologic study
de la Chapelle, A., Kari, C., Nurminen, M., & Hernberg, S. (1977) · Human Genetics · doi:10.1007/bf00393581 · Cited by 211
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1510 · Cited by 200
Gerlach, J., Koppelhus, P., Helweg, E., & Monrad, A. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb09706.x · Cited by 197
Haas, S. J., Hill, R., Krum, H., Liew, D., Tonkin, A., Demos, L., Stephan, K., & McNeil, J. (2007) · Drug Safety · doi:10.2165/00002018-200730010-00005 · Cited by 197
Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (2003) · Focus · doi:10.1176/foc.1.1.37 · Cited by 197
Effects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 196
Clozapine decreases smoking in patients with chronic schizophrenia
McEvoy, J., Freudenreich, O., McGee, M., Vanderzwaag, C., Levin, E., & Rose, J. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00365-a · Cited by 195
VanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., & Lieberman, J. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117424.05703.29 · Cited by 190
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · PubMed · Cited by 189
Childhood-Onset Schizophrenia: An NIMH Study in Progress
Gordon, C. T., Frazier, J. A., McKenna, K., Giedd, J., Zametkin, A., Kaysen, D., Albus, K. E., Rapoport, J. L., Zahn, T., Hong, W., et al. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.4.697 · Cited by 187
Yagcioglu, A. E. A., Akdede, B. B. K., Turgut, T. I., Tümüklü, M., Yazici, M. K., Alptekin, K., Ertugrul, A., Jayathilake, K., Gögüs, A., Tunca, Z., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0109 · Cited by 185
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Idänpään-Heikkilä, J., Alhava, E., Olkinuora, M., & Palva, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90206-8 · Cited by 181
Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics
Atmaca, M., Kuloglu, M., Tezcan, E., & Ustundag, B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0516 · Cited by 181
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178
Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00010-7 · Cited by 177
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Hippius, H. (1989) · Psychopharmacology · doi:10.1007/bf00442551 · Cited by 168
Differential effect of clozapine on weight: a controlled study
Bustillo, J., Buchanan, R. W., Irish, D., & Breier, A. F. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.817 · Cited by 157
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga, C. A., Thaker, G. K., Moran, M. J., Kakigi, T., & Gao, X. (1994) · PubMed · Cited by 156
Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00003 · Cited by 155
Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Clozapine versus typical neuroleptic medication for schizophrenia
Wahlbeck, K., Cheine, M. V., & Essali, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059 · Cited by 144
Self-citationDoes clozapine cause tardive dyskinesia?
Kane, J. M., Woerner, M. G., Pollack, S. Z., Safferman, A. Z., & Lieberman, J. A. (1993) · PubMed · Cited by 139
Gerlach, J., Thorsen, K., & Fog, R. (1975) · Psychopharmacology · doi:10.1007/bf00421473 · Cited by 138
Pinto, A., Pia, S. L., Mennella, R., Giorgio, D., & DeSimone, L. (1999) · Psychiatric Services · doi:10.1176/ps.50.7.901 · Cited by 137
Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia
Litman, R. E., Su, T., Potter, W. Z., Hong, W. W., & Pickar, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.168.5.571 · Cited by 137
Functional effects of antipsychotic drugs: comparing clozapine with haloperidol
Lahti, A. C., Holcomb, H. H., Weiler, M. A., Medoff, D. R., & Tamminga, C. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01602-5 · Cited by 137
An Open Trial of Clozapine in 11 Adolescents with Childhood-Onset Schizophrenia
Frazier, J. A., Gordon, C. T., McKenna, K., Lenane, M., JIH, D., & RAPOPORT, J. L. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199406000-00006 · Cited by 134
Das klinische Wirkungsbild von Clozapin: (Untersuchung mit dem AMP-System)
Angst, J., Bente, D., Berner, P., et al. (1971) · Pharmacopsychiatry · doi:10.1055/s-0028-1094313 · Cited by 133
Elevated Prolactin in Pediatric Patients on Typical and Atypical Antipsychotics
Wudarsky, M., Nicolson, R., Hamburger, S. D., Spechler, L., Gochman, P., Bedwell, J. S., Lenane, M., & RAPOPORT, J. L. (1999) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1999.9.239 · Cited by 133
Bourgeois, M. L., Swendsen, J. D., Young, F. K., AMADOR, X. F., Pini, S., Cassano, G. B., Lindenmayer, J., Hsu, C., Alphs, L. D., Meltzer, H. Y., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1494 · Cited by 131
Hummer, M., Kurz, M., Kurzthaler, I., OBERBAUER, H., Miller, C., & Fleischhacker, W. W. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00012 · Cited by 126
Trichard, C., Martinot, M. P., Attar-Levy, D., Recasens, C., Monnet, F. P., & Martinot, J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.505 · Cited by 125
Спивак, Б., Mester, R., Abesgaus, J., et al. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0706 · Cited by 125
Srisurapanont, M., Maneeton, B., Maneeton, N., Lankappa, S. T., & Gandhi, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967.pub2 · Cited by 122
The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy
Breier, A. F., Buchanan, R. W., Waltrip, R. W., Listwak, S. J., Holmes, C. S., & Goldstein, D. S. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.1 · Cited by 121
Lee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
Clozapine--a new antipsychotic agent.
Simpson, G. M., & Varga, E. (1974) · PubMed · Cited by 120
Small, J. G., Klapper, M. H., Malloy, F. W., & Steadman, T. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084026.22282.5f · Cited by 118
Small, J. G., Milstein, V., Marhenke, J. D., et al. (1987) · PubMed · Cited by 117
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.
Miller, D. D., Fleming, F. J., Holman, T. L., & Perry, P. J. (1994) · PubMed · Cited by 115
Confrontation vs. belief modification in persistently deluded patients
Milton, F., Patwa, V. K., & Hafner, R. J. (1978) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1978.tb02456.x · Cited by 114
Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao, P. A. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110072009 · Cited by 112
Quality of Life in Schizophrenia: A Comparison of Instruments
Cramer, J. A., Rosenheck, R. A., Xu, W., Thomas, J. V., & Henderson, W. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033484 · Cited by 110
Clozapine Eligibility Among State Hospital Patients
Essock, S. M., Hargreaves, W. A., Dohm, F.-A., Goethe, J., Carver, L., & Hipshman, L. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.1.15 · Cited by 107
Clozapine-induced electroencephalogram changes as a function of clozapine serum levels
Freudenreich, O., Weiner, R. D., & McEvoy, J. P. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00298-3 · Cited by 107
Potkin, S. G., Alphs, L. D., Hsu, C., Krishnan, K., Anand, R., Young, F. K., Meltzer, H. Y., & Green, A. I. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00178-1 · Cited by 106
Time to clozapine response in a standardized trial
Conley, R. R., Carpenter, W. T., & Tamminga, C. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1243 · Cited by 106
Zoccali, R. A., Muscatello, M. R. A., Cedro, C., Neri, P., Torre, D. L., Spina, E., Rosa, A. E. D., & Meduri, M. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00003 · Cited by 104
Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns
Breier, A. F., Buchanan, R. W., Irish, D., & Carpenter, W. T. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1249 · Cited by 104
Effects of clozapine on sleep: A longitudinal study
Hinze‐Selch, D., Mullington, J. M., Orth, A., Lauer, C. J., & Pollmächer, T. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00347-2 · Cited by 102
Спивак, Б., Roitman, S., Vered, Y., et al. (1998) · PubMed · Cited by 97
Davies, L. M., & Drummond, M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.162.1.38 · Cited by 96
Arango, C., Breier, A. F., McMahon, R. P., Carpenter, W. T., & Buchanan, R. W. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1421 · Cited by 96
Extrapyramidal side effects of clozapine and haloperidol
Kurz, M., Hummer, M., OBERBAUER, H., et al. (1995) · Psychopharmacology · doi:10.1007/bf02245249 · Cited by 95
Clozapine versus other atypical antipsychotics for schizophrenia
Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633 · Cited by 95
The SKT—A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention
Lehfeld, H., & Erzigkeit, H. (1997) · International Psychogeriatrics · doi:10.1017/s104161029700478x · Cited by 94
Treatment of Late-life Schizophrenia With Neuroleptics
Jeste, D. V., Lacro, J. P., Gilbert, P., Kline, J., & Kline, N. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.4.817 · Cited by 94
Gerlach, J., & Simmelsgaard, H. (1978) · Psychopharmacology · doi:10.1007/bf00427742 · Cited by 93
Prevalence and severity of akathisia in patients on clozapine
Cohen, B. M., Keck, P. E., Satlin, A., & Cole, J. O. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90329-k · Cited by 91
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Conley, R. R., Kelly, D. L., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000096246.29231.73 · Cited by 90
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, S. R., Carter, C., GOLDMAN, R. S., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1013 · Cited by 89
Cost-effectiveness of Clozapine in Patients With High and Low Levels of Hospital Use
Rosenheck, R. A. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.565 · Cited by 86
Essock, S. M., Frisman, L. K., Covell, N. H., & Hargreaves, W. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.987 · Cited by 85
Tauscher, J. T., Kufferle, B., Asenbaum, S., Fischer, P. Q., Pezawas, L., Barnas, C., Tauscher‐Wisniewski, S., Brücke, T., & Kasper, S. F. (1999) · Psychopharmacology · doi:10.1007/s002130050822 · Cited by 84
Rosenheck, R. A., Chang, S. S., Choe, Y., Cramer, J. A., Xu, W., Thomas, J. M., Henderson, W. G., & Charney, D. S. (2000) · PubMed · Cited by 83
Clozapine in China: a review and preview of US/PRC collaboration
Potter, W. Z., Ko, G. N., Zhang, L. D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442568 · Cited by 82
Do Clozapine and Risperidone Affect Social Competence and Problem Solving?
Bellack, A. S., Schooler, N. R., Marder, S. R., Kane, J. M., Brown, C. H., & Yang, Y. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.364 · Cited by 79
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck, R., Dunn, L. A., Peszke, M. A., Cramer, J. A., Xu, W., Thomas, J. V., & Charney, D. S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.88 · Cited by 79
New Drugs for the Treatment of Schizophrenia
Meitzer, H. Y. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30179-5 · Cited by 78
Weickert, T. W., Goldberg, T. E., Marenco, S., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300216 · Cited by 76
Herberg, L. J., & Rose, I. C. (1989) · Psychopharmacology · doi:10.1007/bf00634458 · Cited by 75
Clozapine for the Treatment of Adolescents with Schizophrenia
Birmaher, B. B., BAKER, R., Kapur, S., Quintana, H., & Ganguli, R. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00024 · Cited by 74
Purdon, S. E., Woodward, N. D., Lindborg, S. R., & Stip, É. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1505-z · Cited by 73
Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?
Rosenheck, R. A. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.618 · Cited by 73
Medication Continuation and Compliance
Rosenheck, R. A., Chang, S. S., Choe, Y. H., Cramer, J. A., Xu, W., Thomas, J., Henderson, W. G., & Charney, D. S. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0511 · Cited by 73
Peacock, L., Lublin, H., Gerlach, J., & Solgaard, T. (1996) · Psychopharmacology · doi:10.1007/bf02245620 · Cited by 72
Single- vs Multiple-Dose Pharmacokinetics of Clozapine in Psychiatric Patients
Choc, M. G., Hsuan, F. C., Honigfeld, G., Robinson, W. T., Ereshefsky, L., Crismon, M. L., Saklad, S. R., Hirschowitz, J., & Wagner, R. (1990) · Pharmaceutical Research · doi:10.1023/a:1015859103824 · Cited by 70
Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine
Zahn, T. P., & Pickar, D. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90250-h · Cited by 70
An Open Trial of Clozapine in Thirty-Six Adolescents with Schizophrenia
Remschmidt, H., SCHULZ, E., & MARTIN, P. D. M. (1994) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1994.4.31 · Cited by 70
Ekblom, B., & Häggström, J. E. (1974) · PubMed · Cited by 70
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
Clozapine-Induced Increase in Plasma Levels of Soluble Interleukin-2 Receptors
Pollmächer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220087016 · Cited by 69
Serotonin function and treatment response to clozapine in schizophrenic patients
Kahn, R. S., Davidson, M., Siever, L. J., Gabriel, S. M., Apter, S. H., & Davis, K. L. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1337 · Cited by 68
K�fferle, B., Tauscher, J. T., Asenbaum, S., Vesely, C., Podreka, I., Br�cke, T., & Kasper, S. F. (1997) · Psychopharmacology · doi:10.1007/s002130050409 · Cited by 68
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine
Meltzer, H. Y., Lee, M. A., Ranjan, R., Mason, E. A., & Cola, P. A. (1996) · Psychopharmacology · doi:10.1007/bf02245619 · Cited by 67
Spivak, B., Mester, R., Wittenberg, N., Maman, Z., & Weizman, A. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199710000-00009 · Cited by 67
Clozapine Enhances Neurocognition and Clinical Symptomatology More Than Standard Neuroleptics
Potkin, S. G., Fleming, K., Jin, Y., & Gulasekaram, B. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00004 · Cited by 67
Pharmacological interventions for clozapine-induced hypersalivation
Sheriff, R. S., Au, K., Cahill, C., Duggan, L., He, Y., Udu, V., & Xia, J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005579.pub2 · Cited by 66
Mechanism of Peripheral Noradrenergic Stimulation by Clozapine
Elman, I. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00047-5 · Cited by 64
Weight Gain With Clozapine Compared to First Generation Antipsychotic Medications
Covell, N. H., Weissman, E. M., & Essock, S. M. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007074 · Cited by 62
Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer, J. A., Rosenheck, R. A., Xu, W., Henderson, W., Thomas, J. V., & Charney, D. S. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006869 · Cited by 62
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
A Two-Year Clinical and Economic Follow-Up of Patients on Clozapine
Honigfeld, G., & Patin, J. R. (1990) · Psychiatric Services · doi:10.1176/ps.41.8.882 · Cited by 59
Olanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 59
Clozapine in the treatment of 121 out-patients
Leppig, M., Bosch, B., Naber, D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442565 · Cited by 58
Serum Antimuscarinic Activity During Clozapine Treatment
de León, J., Odom-White, A., Josiassen, R. C., Díaz, F. J., Cooper, T. B., & Simpson, G. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085405.08426.73 · Cited by 58
Carlson, C. D., Cavazzoni, P. A., Berg, P. H., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0807 · Cited by 58
Goldberg, T. E., Dodge, M. R., Aloia, M. S., Egan, M. F., & Weinberger, D. R. (2000) · Psychological Medicine · doi:10.1017/s0033291799002639 · Cited by 58
Piscitelli, S. C., Frazier, J. A., McKenna, K., Albus, K. E., Grothe, D. R., Gordon, C. T., & Rapoport, J. L. (1994) · PubMed · Cited by 57
Litman, R. E., Hommer, D. W., Radant, A. D., Clem, T., & Pickar, D. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90068-x · Cited by 57
Clozapine withdrawal rebound psychosis.
Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56
Suicide and Schizophrenia: Clozapine and the InterSePT Study
Meltzer, H. Y. (1999) · The Journal of Clinical Psychiatry · Cited by 56
McAllister, C. G. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810100098019 · Cited by 54
Meltzer, H. Y., & Jayathilake, K. (1999) · PubMed · Cited by 53
Adverse effects of risperidone and haloperidol treatment in schizophrenia
Yen, Y., Lung, F., & Chong, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.006 · Cited by 53
Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Annals of Clinical Psychiatry · doi:10.1023/b:acli.0000008171.90644.f8 · Cited by 53
Markianos, M., Hatzimanolis, J., & Lykouras, L. P. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060170049 · Cited by 52
Glick, I. D., Zaninelli, R., Hsu, C., Young, F. K., Weiss, L., Günay, İ., & Kumar, V. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0513 · Cited by 52
Response to clozapine in chronic psychotic patients.
Rr, O., Beake, B., Marby, D. W., et al. (1989) · PubMed · Cited by 52
Meltzer, H. Y. (1999) · PubMed · Cited by 51
Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial
Kane, J. M., Honigfeld, G., Singer, J. W., Meltzer, H. Y., & the Clozaril Collaborative Study Group (1989) · Psychopharmacology · doi:10.1007/bf00442561 · Cited by 51
Davidson, M., Kahn, R., Stern, R. G., Hirschowitz, J., Apter, S. H., Knott, P. J., & Davis, K. L. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90017-b · Cited by 50
Glucose effects on cognition in schizophrenia
Stone, W. S., Seidman, L. J., Wojcik, J., & Green, A. I. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00406-1 · Cited by 49
Poor neuroleptic response in acutely exacerbated schizophrenic patients
Shalev, A. Y., Hermesh, H., Rothberg, J. M., & Munitz, H. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03335.x · Cited by 49
Cited by
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Metadata
- Authors
- Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 2010
- Issue
- 1
- Pages
- CD000059-CD000059
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2135182273
- Cited by
- 329
- References
- 259
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.